Flatlander schreef op 28 juli 2021 23:54:
Looks like Promega beats BCART out of the gate with their FDA MSI approval.
FL
FDA Clears Promega Microsatellite Instability Test System
Jul 28, 2021 | staff reporter
NEW YORK – Promega announced on Wednesday that the US Food and Drug Administration has cleared its OncoMate MSI Dx Analysis System. The microsatellite instability diagnostic can now be used to screen for Lynch syndrome in colorectal cancer patients, the Madison, Wisconsin-based firm said.
www.genomeweb.com/pcr/fda-clears-prom...